Company research
Virax Biolabs Group Ltd
CIK 1885827Updated Nov 14, 2026
VRAX price & chart
Loading TradingView…
NASDAQ:VRAX on TradingView ↗About the company
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune™, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.
In the news
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -6,067,232Source | -6,739,120Source | -5,457,763Source | -1,749,870Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 337,576Source | — | — | 928Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | 129,276Source | -572,246Source | — | 641,156Source |
| AdjustmentsForSharebasedPaymentsUSD | 365,309Source | 1,011,973Source | 1,734,601Source | 290,364Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | 123,743Source | 3,668Source | 111Source | 5,657Source |
| GeneralAndAdministrativeExpenseUSD | 4,330,028Source | 4,594,743Source | 5,307,671Source | 1,286,118Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | -78,953Source | 6,104Source | 15,468Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 107,756Source | 56,366Source | — | — |
| ProceedsFromIssuingSharesUSD | 5,128,186Source | 234Source | 13,654,347Source | 519,613Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | — | — | 178,403Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source | —Source | — |
| Total Revenue | — | — | — | — |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | -1.62Source | -3.36Source | -0.51Source | — |
| DepreciationAndAmortisationExpenseUSD | 266,601Source | 54,870Source | — | — |
| DilutedEarningsLossPerShareUSD per share | -1.62Source | -3.36Source | -0.51Source | — |
| EmployeeBenefitsExpenseUSD | 365,309Source | 1,011,973Source | 1,734,601Source | — |
| GeneralAndAdministrativeExpenseUSD | 4,330,028Source | 4,594,743Source | 5,307,671Source | 1,286,118Source |
| GrossProfitUSD | -53,067Source | 50,590Source | -1,365Source | — |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | 390,355Source | — | — |
| IncomeTaxExpenseContinuingOperationsUSD | -136,661Source | — | — | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 45,600Source | 26,347Source | — | — |
| ProfitLossAttributableToNoncontrollingInterestsUSD | -5,985Source | -5,583Source | -269Source | -41,043Source |
| ProfitLossAttributableToOwnersOfParentUSD | -6,061,247Source | -6,733,537Source | -5,457,494Source | -1,708,827Source |
| ProfitLossBeforeTaxUSD | -6,203,893Source | -6,739,120Source | -5,457,763Source | -1,749,870Source |
| ProfitLossFromOperatingActivitiesUSD | -6,162,897Source | -6,496,473Source | -5,732,761Source | -1,733,679Source |
| ResearchAndDevelopmentExpenseUSD | 1,779,802Source | 1,561,965Source | 397,109Source | 433,743Source |
| SellingExpenseUSD | — | — | 26,616Source | 13,818Source |
Offerings
Registration 333-297684
Filing attachments
vrax-ex99_1.htm · 6-K · 2026-11-13
Exhibit 99.1 Virax Biolabs Group Limited (Incorporated under the laws of the Cayman Islands) Notice of Extraordinary General Meeting of Shareholders To Be Held on November 27, 2026, at 2:00 p.m., local time NOTICE IS HEREBY GIVEN THAT the Extraordinary General Meeting (the “Meeting”) of the holders (the "shareholders") of the ordinary shares of par value US$0.025 each (the “Ordinary Shares”) of Virax Biolabs Group Limited (the “Company”) will be held at BioCity Glasgow, Bo’Ness Road, Newhou…
Read attachment ↗vrax-ex99_1.htm · 6-K · 2026-10-29
Exhibit 99.1 Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China Three new distributor agreements build on initial China sales and extend the Company’s distributor-led commercial strategy LONDON, 29 October, 2026 /PRNewswire/ - Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that, through its China subsidiary, Shanghai Xitu Consulting Co., Ltd., it has entered into non-exclusive distribution agreements with AmyJe…
Read attachment ↗vrax-ex99_1.htm · 6-K · 2026-07-31
Exhibit 99.1 Virax Biolabs Group Limited (Incorporated under the laws of the Cayman Islands) Notice of Extraordinary General Meeting of Shareholders To Be Held on August 14, 2026, at 2:00 p.m., local time NOTICE IS HEREBY GIVEN THAT the Extraordinary General Meeting (the “Meeting”) of the holders (the "shareholders") of the ordinary shares of par value US$0.025 each (the “Ordinary Shares”) of Virax Biolabs Group Limited (the “Company”) will be held at BioCity Glasgow, Bo’Ness Road, Newhouse…
Read attachment ↗vrax-ex99_1.htm · 6-K · 2026-07-16
Exhibit 99.1 Virax Biolabs’ CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement - Fiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders’ equity attributable to ordinary shareholders of $7.3 million - Fosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian markets - Preferred …
Read attachment ↗